Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007

Neuro-Oncology

Volumn 15, Issue 3, 2013, Pages 330-340

  Towner, Rheal A ^a   Gillespie, David L ^c   Schwager, Andrea ^d   Saunders, Debra G ^a   Smith, Nataliya ^a   Njoku, Charity E ^a   Krysiak, Richard S ^a   Larabee, Chelsea ^a   Iqbal, Henna ^a   Floyd, Robert A ^a   Bourne, David W A ^b   Abdullah, Osama ^d   Hsu, Edward W ^d   Jensen, Randy L ^c,d  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

anti glioma therapy; bioluminescence imaging; F98 rat glioma model; in vivo; magnetic resonance imaging; nitrone OKN 007; U87 xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; CASPASE 3; DISODIUM 4 [(TERT BUTYL IMINO)METHYL]BENZENE 1,3 DISULFONATE N OXIDE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; NITRONE DERIVATIVE; OKN 007; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG HALF LIFE; GLIOMA; HYPOXEMIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SURVIVAL RATE;

ANIMALS; APOPTOSIS; BENZENESULFONATES; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; GLIOMA; HUMANS; IMINES; IMMUNOENZYME TECHNIQUES; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED F344; RATS, NUDE; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84874535509     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos337     Document Type: Article

References (27)

1. Central Brain Tumor Registry of the United States (CBTRUS). 2011 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. 2011.
2. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics. 2010;73(10):1823-1838.
3. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of singleagent and combined modality approaches. Radiat Oncol. 2011;6:2.
4. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials. 2010;5(1):14-27.
5. Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel therapies in glioblastoma. Neurol Res Int. 2012;2012:428565.
6. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119-4124.
7. Floyd RA, Chandru HK, He T, Towner R. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem. 2011;11(4):373-379.
8. Floyd RA, Kopke RD, Choi CH, Foster SB, Doblas S, Towner RA. Nitrones as therapeutics. Free Radic Biol Med. 2008;45(10):1361-1374.
9. Garteiser P, Doblas S, Watanabe Y, et al. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Reson Imaging. 2010;31(4):796-806.
10. Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. 2011;3(3):e00063.
11. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36(1):91-102. (Pubitemid 28230658)
12. Barth RF, Kaur B. Rat brain tumor models in experimental neurooncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 2009;94(3):299-312.
13. Yurek DM, Fletcher AM, McShane M, et al. DNA nanoparticles: detection of long-term transgene activity in brain using bioluminescence imaging. Mol Imaging. 2011;10(5):327-339.
14. Doblas S, He T, Saunders D, et al. In vivo characterization of several rodent glioma models by (1) H MRS. NMR Biomed. 2012;25(4):685-694.
15. Towner RA, Smith N, Doblas S, et al. In vivo detection of inducible nitric oxide synthase in rodent gliomas. Free Radic Biol Med. 2010;48(5): 691-703.
16. Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032-1042.
17. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 2007;13(8): 2441-2448. (Pubitemid 46698595)
18. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 2002;135(1):103-112. (Pubitemid 34102103)
19. Bourne DW. BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed. 1989;29(3):191-195. (Pubitemid 19210988)
20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6(2):165-175. (Pubitemid 8384279)
21. Hashizume R, Ozawa T, Dinca EB, et al. A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol. 2010;96(2):151-159.
22. Maples KR, Green AR, Floyd RA. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs. 2004;18(15):1071-1084. (Pubitemid 40007491)
23. Wemer J, Cheng YF, Nilsson D, et al. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin. 2006;22(9):1813-1823. (Pubitemid 44449238)
24. Fong JJ, Rhoney DH. NXY-059: review of neuroprotective potential for acute stroke. Ann Pharmacother. 2006;40(3):461-471.
25. He T, Doblas S, Saunders D, et al. Effects of PBN and OKN007 in rodent glioma models assessed by 1H MR spectroscopy. Free Radic Biol Med. 2011;51(2):490-502.
26. Asanuma T, Doblas S, Tesiram YA, et al. Visualization of the protective ability of a free radical trapping compound against rat C6 and F98 gliomas with diffusion tensor fiber tractography. J Magn Reson Imaging. 2008;28(3):574-587.
27. Culot M, Mysiorek C, Renftel M, et al. Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. Brain Res. 2009;1294:144-152.